WASHINGTON: A US center for the disease control and prevention advisory panel will meet on Thursday to consider the possibility of limitations about the use of Johnson & Johnson Covid-19 vaccine due to sustainable blood clots issues, the Washington Post reported on Wednesday.
The CDC Advisory Committee about Immunization Practices will be presented new data that seems to show a clot level in people who receive Johnson & Johnson vaccine has increased since April, the post is reported, quoting a doctor with an agenda.
The use of vaccines in the United States was published for 10 days in April to investigate very rare but potentially deadly lumps, mostly in young and middle-aged women.
There were around nine deaths related to this problem, said posting, quoting a federal official who was not named.
CDC did not immediately respond to requests from Reuters to comment on posts.
US CDC advisor to consider limit on the J & J vaccine due to blood clot problems
